PeptidePedia The community reference

Talk:MOTS-c

Discussion page·2 threads·no archives

This article is within the scope of the pharmacology working group.

This is the discussion page for the article MOTS-c. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Preclinical to human gapResolved

"The gap should not be closed by inference" is the sentence this article needed. Rodent metabolic findings translate poorly and the literature here is almost entirely rodent. — MOTSc_Mira (talk) 09:40, 4 February 2026 (UTC)

And the cross-sectional human associations are labelled as unable to establish direction. ✓ Done — PrimarySrcPatia (talk) 13:15, 4 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Assay comparabilityDone

Pointing at the glucagon assay problem as a worked example of peptide immunoassay disagreement is a good reuse of material we already have. — AnalyticalAnnie (talk) 10:25, 7 May 2026 (UTC)

Linked. It saves this article from restating the whole argument. ✓ Done — CrossRefCleve (talk) 14:00, 7 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 7 May 2026, by CrossRefCleve. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).